Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-363856 in Adults with Generalized Anxiety Disorder
jRCT2031230152Phase 3Active, not recruiting
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Aug 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in generalized anxiety disorder (GAD) comparing SEP-363856 with Placebo (2 arms). Primary endpoint: Change from Baseline in HAM-A total score at Week 8. Started Aug 2023; status: active, not recruiting.
02
Drugs
ulotaront
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on jRCT2031230152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230152.